Lonza, a global development and manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced the completion of the first GMP product batch supported from the recently completed next-generation mammalian manufacturing facility in Portsmouth (US). 

The first GMP batch release marks a significant milestone, allowing the facility to help meet the increasing market demand for small- to mid-scale volumes of mammalian-derived biologics and support the implementation of high-titer and high-throughput platform processes.

Stefan Egli, Head of Mammalian Business Unit, Lonza, commented: “We are excited to have completed the first GMP batch at our Portsmouth facility. This milestone is a testament to our commitment to delivering industry-leading manufacturing services to our customers, highlighting our continued efforts to support our customers’ needs across their product lifecycle and meet growing market demand for the launch scale. The new 2,000L asset will support small- to mid-volume products, such as innovative therapies targeting rare diseases, and provides the flexibility required for efficient product launches and sustainable lifecycle management across our manufacturing network.”